CSL shares hit lowest since 2017 after Pentagon flu policy change

Australian biotechnology company CSL saw a sharp decline in its shares following a change in the US Department of Defense's (Pentagon) flu vaccine policy. The company's shares fell to their lowest level since 2017, alarming investors. The Pentagon's shift in flu vaccine procurement strategy negatively impacted CSL's contracts in this area. The company was a key supplier of flu vaccines to the US military. The policy change has led to a reduction in CSL's share of this market. CSL's share performance rapidly lost value after the news. Analysts note that the Pentagon's decision could affect the company's short-term revenues. However, CSL's diversification across other product groups may offset this impact in the long term. The company has not made an official statement on the matter, while investors await details of the Pentagon's new policy. CSL's activities outside of flu vaccines, particularly blood plasma products, account for a significant portion of the company's total revenue. This is not investment advice.